The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-months follow-up
Guardado en:
Autores principales: | Pankaj Jariwala, Kartik Jadhav, Saket Khetan, Maturu Nagarjuna |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fd73bb39eae542d38965e5cbc3a41502 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The safety and efficacy of fimasartan in Indian patients with systemic arterial hypertension
por: Pankaj Jariwala, et al.
Publicado: (2021) -
The safety and efficacy of efonidipine, an L- and T-type dual calcium channel blocker, on heart rate and blood pressure in Indian patients with mild-to-moderate essential hypertension
por: Pankaj Jariwala, et al.
Publicado: (2021) -
The effectiveness and tolerability of switching Indian patients from sacubitril/valsartan, ARNI to perindopril in heart failure with reduced ejection fraction. [Efficient study]
por: Pankaj Jariwala, et al.
Publicado: (2021) -
Unexpected use of ‘additional-stent’ during elective percutaneous coronary intervention
por: Kartik Jadhav, et al.
Publicado: (2021) -
Safety and effectiveness of angiotensin receptor-neprilysin inhibitors (ARNI) in patients with heart failure with preserved ejection fraction (HFPEF) – ‘ARNI-preserved’ study
por: Pankaj Jariwala, et al.
Publicado: (2021)